¼¼°èÀÇ ´Ü¹éÁú ¿£Áö´Ï¾î¸µ ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ - Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, ±â¼úº°, ´Ü¹éÁú À¯Çüº°, Áö¿ªº° Àü¸Á ¹× ¿¹Ãø(2024-2031³â)
Global Protein Engineering Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents, and Software & Services), By End-use, By Technology, By Protein Type, By Regional Outlook and Forecast, 2024 - 2031
»óǰÄÚµå : 1498431
¸®¼­Ä¡»ç : KBV Research
¹ßÇàÀÏ : 2024³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 320 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,600 £Ü 5,023,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,320 £Ü 6,028,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,048 £Ü 8,439,000
PDF (Corporate User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

´Ü¹éÁú ¿£Áö´Ï¾î¸µ ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È 16.0%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ½ÃÀå ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 2031³â±îÁö 78¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀº ÇコÄÉ¾î ¾÷°èÀÇ µðÁöÅÐ ÀüȯÀ» °¡¼ÓÈ­ÇÏ¿© ÀÌ ¿£Áö´Ï¾î¸µ¿¡ À־ÀÇ °è»ê Åø°ú ÀΰøÁö´ÉÀÇ È°¿ëÀ» È®´ëÇß½À´Ï´Ù. ÀÌ µðÁöÅÐÈ­·Î ÀÌ·¯ÇÑ ¿£Áö´Ï¾î¸µ ÇÁ·Î¼¼½º¸¦ °£¼ÒÈ­Çϰí, °³¹ß ±â°£À» ´ÜÃàÇÏ¿©, ½Å¾àÀÇ ¹ß°ß ¹× °³¹ß ³ë·ÂÀÇ È¿À²¼ºÀ» ³ôÀÏ °¡´É¼ºÀ» ³º¾Ò½À´Ï´Ù. ÀÇ·á »ê¾÷ÀÌ µðÁöÅÐ ±â¼úÀ» äÅÃÇÔ¿¡ µû¶ó ÀÌ·¯ÇÑ ±â¼úÀ» Ȱ¿ëÇÑ ¿£Áö´Ï¾î¸µ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çß½À´Ï´Ù. µû¶ó¼­ ÆÒµ¥¹ÍÀº ½ÃÀå¿¡ Àü¹ÝÀûÀ¸·Î ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

±×·¯³ª Àΰø ´Ü¹éÁú °³¹ß¿¡´Â °í±Þ ½ÇÇè½Ç Àåºñ, ¼÷·ÃµÈ ÀηÂ, Á¶»ç ÀÚ·á, ÀÎÇÁ¶ó µî ´Ù¾çÇÑ ºÐ¾ß¿¡ ¸¹Àº ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀΰǺñµµ ¿£Áö´Ï¾î¸µÀÇ ¿¬±¸°³¹ß¿¡ Å©°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ ¿£Áö´Ï¾î¸µ ±â¼ú¿¡ Àͼ÷ÇÑ ¼÷·ÃµÈ °úÇÐÀÚ, »ý¸í°øÇÐÀÚ, ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º Àü¹®°¡¸¦ äÅÃÇϰí À¯ÁöÇÏ·Á¸é ƯÈ÷ ÀÎÀç ȹµæ °æÀïÀÌ ½ÉÇÑ Áö¿ª¿¡¼­´Â ºñ¿ëÀÌ ¸¹ÀÌ µé ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ¿äÀÎÀº ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

Á¦Ç°º° Àü¸Á

Á¦Ç°¿¡ µû¶ó ½ÃÀåÀº Àåºñ, ½Ã¾à, ¼ÒÇÁÆ®¿þ¾î ¹× ¼­ºñ½º·Î ºÐ·ùµË´Ï´Ù. ½Ã¾à ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 35%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. È¿¼Ò, Ç×ü, ¿ÏÃæ¾×, ±âÁú µîÀÇ ½Ã¾àÀº ¿£Áö´Ï¾î¸µ ½ÇÇè¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀçÁ¶ÇÕ DNA ±â¼ú°ú ´Ü¹éÁú ¹ßÇö ½Ã½ºÅÛÀÇ Ã¤¿ëÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °íǰÁú ½Ã¾à¿¡ ´ëÇÑ ¼ö¿ä°¡ ÃËÁøµÇ°í ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» Áö¿øÇÕ´Ï´Ù.

ÃÖÁ¾ ¿ëµµº° Àü¸Á

ÃÖÁ¾ ¿ëµµ¿¡ µû¶ó ½ÃÀåÀº Çмú¿¬±¸±â°ü, ¼öŹÁ¶»ç±â°ü(CRO), Á¦¾à ¹× »ý¸í°øÇбâ¾÷À¸·Î ºÐ·ùµË´Ï´Ù. À§Å¹Á¶»ç±â°ü(CRO) ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 38.5%ÀÇ ¼öÀÍ Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù. CRO´Â Á¦¾à, »ý¸í°øÇÐ, Çмú¿¬±¸±â°ü¿¡ ¿£Áö´Ï¾î¸µ ¼­ºñ½º¸¦ Á¦°øÇÏ´Â µ¥ ÇʼöÀûÀÌ¸ç ´Ü¹éÁúÀÇ ¼³°è, ¹ßÇö, Á¤Á¦, Ư¼ºÈ­¿¡ °üÇÑ Àü¹® Áö½Ä°ú ÀÚ¿øÀ» Á¦°øÇÕ´Ï´Ù.

±â¼úº° Àü¸Á

±â¼úÀ» ¹ÙÅÁÀ¸·Î ½ÃÀåÀº ÇÕ¸®ÀûÀÎ ´Ü¹éÁú ¼³°è, ÁöÇ⼺ ÁøÈ­, ÇÏÀ̺긮µå Á¢±Ù¹ý, µ¥³ëº¸ ´Ü¹éÁú ¼³°è µîÀ¸·Î ºÐ·ùµË´Ï´Ù. ÇÏÀ̺긮µå Á¢±Ù ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 34.2%ÀÇ ¼öÀÍ Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù. ÇÏÀ̺긮µå Á¢±Ù¹ýÀº ÇÕ¸®ÀûÀÎ ´Ü¹éÁú ¼³°è¿Í ÁöÇ⼺ ÁøÈ­ÀÇ ¿ä¼Ò¸¦ °áÇÕÇÏ°í °è»ê ¸ðµ¨¸µ°ú ½ÇÇèÀû ÁøÈ­¸¦ Ȱ¿ëÇÏ¿© °³¼±µÈ ±â´É ¶Ç´Â »õ·Î¿î ±â´ÉÀ» °¡Áø ´Ü¹éÁúÀ» ¼³°èÇÕ´Ï´Ù.

´Ü¹éÁú À¯Çüº° Àü¸Á

´Ü¹éÁú À¯Çüº°·Î º¼ ¶§ ½ÃÀåÀº Àν¶¸°, ´ÜŬ·ÐÇ×ü, ¹é½Å, ¼ºÀå ÀÎÀÚ, ½Ä¹ÎÁö ÀÚ±Ø ÀÎÀÚ, ÀÀ°í ÀÎÀÚ, ÀÎÅÍÆä·Ð µîÀ¸·Î ³ª´µ¾îÁ® ÀÖ½À´Ï´Ù. Àν¶¸° ºÎ¹®Àº 2023³â ½ÃÀå¿¡¼­ 16.75%ÀÇ ¼öÀÍ Á¡À¯À²À» ȹµæÇß½À´Ï´Ù. ´ç´¢º´ ȯÀÚÀÇ »ý¸íÀ» ±¸ÇÏ´Â Ä¡·á¿ë ´Ü¹éÁúÀÎ Àν¶¸°Àº ¸¸¼º Áúȯ °ü¸®¿¡ À־ ÀÌ °øÇÐÀÇ Áß¿äÇÑ ¿ªÇÒÀ» º¸¿©ÁÝ´Ï´Ù. ¿£Áö´Ï¾î¸µÀÇ Áøº¸·Î ÀÎü ³»Àμº Àν¶¸° ºÐºñ¿¡ ´õ °¡±î¿î ´Ù¾çÇÑ Àν¶¸° Á¦ÇüÀÌ »ý¼ºµÇ¾ú½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹üÀ§ ¹× Á¶»ç ¹æ¹ý

Á¦2Àå ½ÃÀå ¿ä¶÷

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå ¼¼°è ½ÃÀå : Á¦Ç°º°

Á¦5Àå ¼¼°è ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

Á¦6Àå ¼¼°è ½ÃÀå : ±â¼úº°

Á¦7Àå ¼¼°è ½ÃÀå : ´Ü¹éÁú À¯Çüº°

Á¦8Àå ¼¼°è ½ÃÀå : Áö¿ªº°

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦10Àå ´Ü¹éÁú ¿£Áö´Ï¾î¸µ ½ÃÀå¿¡¼­ÀÇ ¼º°ø Çʼö Á¶°Ç

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Protein Engineering Market size is expected to reach $7.8 billion by 2031, rising at a market growth of 16.0% CAGR during the forecast period.

Protein engineering is crucial in developing and optimizing growth factors, signaling proteins that regulate cell growth, proliferation, and differentiation. This engineering has been used to develop novel growth factors with enhanced specificity and potency. Consequently, the growth factors segment would acquire nearly 12% of the total market share by 2031. To enhance its effectiveness in promoting blood vessel formation, for instance, scientists have engineered variants of vascular endothelial growth factor (VEGF), a key regulator of angiogenesis.

By abandoning the conventional "one-size-fits-all" approach in favor of a more individualized treatment paradigm, personalized medicine is currently transforming the healthcare infrastructure. Personalized medicine harnesses the power of genomic and molecular data to guide clinical decisions. By analyzing a patient's genetic profile, healthcare providers can identify specific genetic mutations, biomarkers, and pathways involved in their disease. Therefore, with the continuous evolution of this engineering and genomic technologies, the potential for personalized medicine to revolutionize healthcare and enhance patient outcomes will inevitably expand, propelling the market's expansion. Additionally, Innovations in technologies like CRISPR, synthetic biology, and computational protein design enhance the ability to engineer proteins with desired characteristics. Synthetic biology has been used to engineer yeast and bacteria to produce complex pharmaceuticals like artemisinin, an antimalarial drug, which traditionally had a complex and costly extraction process from plants. Thus, the advancements in this engineering technologies like CRISPR, synthetic biology, and computational protein design are driving significant growth in the market.

The COVID-19 pandemic accelerated the digital transformation of the healthcare industry, leading to greater utilization of computational tools and artificial intelligence in this engineering. This digitalization brought the potential to streamline this engineering process, reduce development timelines, and enhance the efficiency of drug discovery and development efforts. The demand for engineering solutions that leverage these technologies grew as the healthcare industry embraced digital technologies. Therefore, the pandemic had an overall positive impact on the market.

However, Developing engineered proteins requires substantial investment in various areas, including advanced laboratory equipment, skilled personnel, research materials, and infrastructure. Personnel costs also contribute significantly to the engineering R&D. Recruiting and retaining skilled scientists, biotechnologists, and bioinformaticians proficient in this engineering techniques can be costly, especially in regions with high competition for talent. Hence, these factors may hamper the growth of the market.

Product Outlook

Based on product, the market is characterized into instruments, reagents, and software & services. The reagents segment procured 35% revenue share in the market in 2023. Reagents, including enzymes, antibodies, buffers, and substrates, are essential in the engineering experiments. The increasing adoption of recombinant DNA technology and protein expression systems has driven the demand for high-quality reagents, supporting the growth of this segment.

End-use Outlook

Based on end-use, the market is segmented into academic research institutes, contract research organizations (CROs), pharmaceutical & biotechnology companies. The contract research organizations (CROs) segment witnessed 38.5% revenue share in the market in 2023. CROs are vital in providing the engineering services to pharmaceutical, biotechnology, and academic research institutions, offering expertise and resources for protein design, expression, purification, and characterization.

Technology Outlook

On the basis of technology, the market is classified into rational protein design, directed evolution, hybrid approach, de novo protein design, and others. The hybrid approach segment recorded 34.2% revenue share in the market in 2023. The hybrid approach combines elements of rational protein design and directed evolution, leveraging computational modeling and experimental evolution to engineer proteins with improved or novel functions.

Protein Type Outlook

By protein type, the market is divided into insulin, monoclonal antibodies, vaccines, growth factors, colony stimulating factors, coagulation factors, interferon, and others. The insulin segment garnered 16.75% revenue share in the market in 2023. Insulin, a life-saving therapeutic protein for diabetic patients, exemplifies the crucial role of this engineering in chronic disease management. The engineering advancements have produced a variety of insulin formulations that more closely resemble the body's endogenous insulin secretion.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered 39.8% revenue share in the market in 2023. The region's strong biotechnology and pharmaceutical sectors, in addition to substantial investments in the engineering research and development, are factors contributing to this.

List of Key Companies Profiled

Global Protein Engineering Market Report Segmentation

By Product

By End-use

By Technology

By Protein Type

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Global Protein Engineering Market by Product

Chapter 5. Global Protein Engineering Market by End-use

Chapter 6. Global Protein Engineering Market by Technology

Chapter 7. Global Protein Engineering Market by Protein Type

Chapter 8. Global Protein Engineering Market by Region

Chapter 9. Company Profiles

Chapter 10. Winning Imperatives for Protein Engineering Market

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â